TipRanks
Go Ultimate55% OFF

Josh Mandel-Brehm Insider Profile

4 Followers

Josh Mandel-Brehm, CEO, Director at CAMP4 Therapeutics Corporation, holds 284.97K shares in CAMP4 Therapeutics Corporation (Ticker: CAMP), holds ― shares in ProMIS Neurosciences (Ticker: PMN). Most recently, Josh Mandel-Brehm Bought ― shares of CAMP4 Therapeutics Corporation on Aug 05, 2026 for an estimated value of $10.81K.

Josh Mandel-Brehm's Trading History

CAMP
CAMP4 Therapeutics Corporation
Aug 05, 2026CEO, DirectorInformative Buy10.81K$1.13M
PMN
ProMIS Neurosciences
―Director――

You May Also Like

Josh Mandel-Brehm insider profile FAQ

What is the percentage of profitable transactions made by Josh Mandel-Brehm?
The percentage of profitable transactions made by Josh Mandel-Brehm is 50%.
What is the average return per transaction made by Josh Mandel-Brehm?
The average return per transaction made by Josh Mandel-Brehm is 25.80%.
What stocks does Josh Mandel-Brehm hold?
Josh Mandel-Brehm holds: CAMP, PMN stocks.
What was Josh Mandel-Brehm’s latest transaction?
Josh Mandel-Brehm’s latest transaction was an Informative Buy of $10.81K.
What was Josh Mandel-Brehm's most profitable transaction?
Josh Mandel-Brehm’s most profitable transaction was an Informative Buy of CAMP stock on September 11, 2025. The return on the trade was 52.80%.
What is Josh Mandel-Brehm's role in CAMP4 Therapeutics Corporation?
Josh Mandel-Brehm's role in CAMP4 Therapeutics Corporation is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.